Peptides›GH-stack›PEG-MGF

PEG-MGF

/ PEGylated synthetic peptide (MGF E-domain 24mer with PEG conjugation; PEG MW unspecified by vendors)

TIER 3 · PreclinicalN = 0 · TESTING PENDING

ALIAS · PEGylated Mechano Growth Factor · PEGylated IGF-1Ec E-domain peptide

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequenceYQPPSTNKNTKSQRRKGSTFEERK (PEG conjugation site and PEG MW vary by vendor)

MW · —CLASS · PEGylated synthetic peptide (MGF E-domain 24mer with PEG conjugation; PEG MW unspecified by vendors)CATEGORY · GH-stack

Tier 3 (animal/in-vitro inference). PEG-MGF is the synthetic 24-residue MGF E-domain peptide with a polyethylene glycol modification claimed to extend half-life. The PEGylated form has no peer-reviewed pharmacokinetic or efficacy data published independently of vendor marketing.

§ B · Mechanism of action

The PEGylation rationale is to slow renal clearance and proteolytic degradation of the MGF E-domain peptide. The base peptide (synthetic MGF 24mer) has been studied in rodent and in-vitro models for muscle satellite-cell proliferation effects (see MGF page); the PEG addition is a delivery hypothesis without published validation.

§ C · Human clinical evidence

Inferred from MGF base-peptide literature only. No published PK study comparing PEG-MGF half-life versus unmodified MGF in any species.

§ D · Primary literature

PubMed12095637Yang SY et al. — Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation · FEBS Letters · in-vitroSynthetic E-domain peptide of IGF-IEc (MGF) increased C2C12 myoblast proliferation but blocked differentiation, while mature IGF-I had the inverse effect — foundational evidence for distinct splice-variant roles.Limitations: Single cell line, in-vitro only; no PEGylated long-acting variants tested.2002

§ F · Safety signal

No safety database. PEGylation introduces its own class concerns (anti-PEG antibodies, possible hypersensitivity in PEG-sensitised individuals) on top of the unknown base-peptide safety profile.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

The PEGylation half-life-extension claim is plausible by analogy to other PEGylated peptides (PEG-IFN, PEG-asparaginase, etc.) but has no direct evidence for MGF. Vendor product specifications (PEG MW, conjugation site, conjugation efficiency) are typically not disclosed.